Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021
WATERTOWN, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated...
News
Amolyt Pharma Announces Appointment of Two Directors
Elisabeth Svanberg, M.D., Ph.D. brings extensive experience in the development of therapeutics for under-served endocrine, metabolic and other diseases James...
BeyondSpring to Participate in the William Blair Biotech Focus Conference
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the...
Certara Announces Update of BaseCase Software, the Company’s Value Communication Platform
Major Release to Help Life Science Companies Maximize Go-to-Market ImpactPRINCETON, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Certara, a global...
Healthtech Solutions, Inc. Adds Distinguished Leadership To Its Board of Directors
Steve Horowitz appointed to Board of DirectorsNEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Healthtech Solutions, Inc....
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
Results from proof-of-concept study are expected in September 2021. SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc....
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”),...
Vaccitech to Present at the William Blair Biotech Focus Conference 2021
OXFORD, United Kingdom, July 08, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
Quipt Announces Proceeds From Exercise of Warrants
Proceeds of $17.5 Million Received Over 12-Month Expiration PeriodCINCINNATI, July 08, 2021 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt”...
Ensysce Biosciences Receives Notice of Award for Year Three of Multi-Year NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection
Company’s Proprietary TAAP Prodrug Delivery and Overdose Technology Aims to Stem The Opioid Abuse EpidemicSAN DIEGO, July 08, 2021 (GLOBE...
Tiziana Life Sciences plc – ADS Ex-Dividend Date Scheduled for July 09, 2021
THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc...
Generation Bio to Present at William Blair Biotech Focus Conference
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a...
Windtree to Present at Access to Giving Virtual Investor Conference
WARRINGTON, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused...
ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR...
Helius Medical Technologies, Inc. Appoints Antonella Favit-Van Pelt, M.D., Ph.D. as Chief Medical Officer
NEWTOWN, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech...
Nephros Announces Preliminary Results for Second Quarter of 2021
Anticipates Net Revenue of $2.2 Million, Greater Than 40% Year-Over-Year Increase;Submits HDF Product to FDA for 510(k) Clearance SOUTH ORANGE,...
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementiaCAMBRIDGE, Mass. and...
Better Choice Announces Increased Insider Participation
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE American: BTTR) (“Better Choice”), an animal health and...
Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical
Nhwa is conducting and funding this study to support NDA regulatory filing in China Trevena expects to receive approval and...
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and...